Cancer Research UK launches breast cancer drug study

In collaboration with the Press Association

Cancer Research UK has launched a new study that will investigate the effectiveness of two breast cancer drugs, anastrozole and tamoxifen.

The aim of the study is to compare how well the drugs are able to prevent breast cancer in women who have had ductal carcinoma in situ (DCIS).

The number of women diagnosed with DCIS, a non-invasive form of early breast cancer, has been on the increase.

According to Cancer Research UK figures, the number of cases rose from 2,910 in 1997 to 3,800 in 2002.

Professor Tony Howell, IBIS-2 co-chairman and professor of medical oncology at the Christie hospital, Manchester, said: "Known cases of DCIS are increasing because of the success of the national breast screening programme.

"Although screening must continue, it is of vital importance that we find the best treatment to prevent breast cancer from coming back in this rising number of women and we believe that the IBIS-2 DCIS study will help give us the answers."

The study will be conducted across the world, with researchers looking to trial the two drugs on 4,000 women aged between 40 and 70 who have had a DCIS in the last six months.